“Immunotherapy has grabbed our attention [in oncology], and it is not the end of the story,” declared Anthony J. Olszanski, RPh, MD, Associate Professor, Director of the Phase I Developmental Therapeutics Program, and Director of the Medical Oncology Melanoma Program at Fox Chase Cancer Center. “The future will not be just about immunotherapy, but rather the combination of both immunotherapies and cytotoxic therapies,” predicted Dr. Olszanski, who currently serves on the NCCN Guidelines Panel for Melanoma.
Snyder A, Makarov V, Merghoub T. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-2199.
Schreiber RD. Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. Cancer Immun 2005;5(Suppl 1):1.
Galon J, Costes A, Sanchez-Cabo F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960–1964.
Atkins MB, Lotze MT, Dutcher JP. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105–2116.
Ansell SM, Lesokhin AM, Borrello I. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311–319.
Topalian SL, Sznol M, Brahmer JR. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a phase I trial [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 3002.
Postow MA, Chesney J, Pavlick AC. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015 [e-pub ahead of print].
Segal NH, Antonia SJ, Brahmer JR. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody [abstract]. J Clin Oncol 2014;32(Suppl):Abstract 3002.